No compromise:

Macopharma bans DEHP, to ensure SAFE and SECURED

blood component solutions to every patient in the world!

Full compliance with REACH regulation

Complete engagement to switch to non-DEHP

More than words, we commit to act and respect our mission:

We support life !

At Macopharma,
we consider Non DEHP
transition as INNOVATION.

Because the value of future bag systems is about safety
we have dedicated a full team of scientific experts to research,
design and develop our new kits as a pure

About REACH regulation

REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals) is a regulation of the European Union, adopted to improve the protection of human health and the environment from the risks that can be posed by chemicals.(1)

(1) European Chemicals Agency. Understanding REACH. Available at: Accessed July 2022.

About DEHP

Used for decades, DEHP has a positive effect on the red blood cell membrane integrity and reduces the hemolysis. But the listed toxicological effects have to be considered:(1,2)

Classified as a carcinogenic, mutagenic
or toxic for reproduction (CMR) Ib.

In addition, Endocrine-disrupting effects.

(1) Horowitz B, Stryker MH, Waldman AA, Woods KR, Gass JD, Drago J. Stabilization of red blood cells by the plasticizer, diethylhexylphthalate. Vox Sang 1985; 48:150-5.

(2) AuBuchon JP, Estep TN, Davey RJ. The effect of the plasticizer di-2-ethylhexyl phthalate on the survival of stored RBCs. Blood 1988; 71:448-52. 


* Di(ethylhexyl) terephthalate / phosphate-adenine-glucose-guanosin-saline-mannitol

DEHT has an improved safety profile with no reported mutagenic, carcinogenic or reproductive effects(1,2)

PAGGS-M improves red cell concentrate quality parameters with no reported impact on clinical effectiveness or patient safety(3,4)

DEHT versus DEHP

Improved toxic profile with no mutagenic, carcinogenic or reproductive effects.(1,2)

Associated with lower leaching than DEHP.(5)

Their use is likely to alleviate environmental risks.

Supply risk for DEHP.


Enhanced additive solution that compensates for the impact of haemolysis over time and improves the quality parameters of red cell concentrates (RCC).(3,5)

Used for decades by various entities in Germany.

No reported impact on clinical efficacy and patient safety (DE/CH/AU).(4,6)

(1)Kambia Metabolites 2021; 11:94.

(2)Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR). Opinion on the safety of medical devices containing DEHP plasticised PVC or other plasticisers on neonates and other groups possibly at risk (2015 update). 2017.

(3)Larsson L. Vox Sang. 2021;116:60-70

(4)Flegel WA. Br J Haematol. 2014;165(1):3-16.

(5)Graminske, Transfusion 2018; 58:1100-7.

(6)Hess J. Extended Liquid Storage of Red Blood Cells. In: Manning FJ, Sparacino L, Eds. Blood Donors and the Supply of Blood and Blood Products. Washington DC: The National Academies Press, 1996.